BOEHRINGER-INGELHEIM
Boehringer Ingelheim today announced that the first patient has enrolled in InPedILD™, a global Phase III trial assessing the dosing and safety profile of nintedanib in children and adolescents between six and 17 years old with clinically significant fibrosing interstitial lung disease (ILD).
Childhood ILD (chILD) includes more than 200 rare respiratory disorders that can affect infants, children and adolescents, making it difficult for them to breathe. In some cases, fibrosis which involves scarring and damage to the lungs can develop. This can lead to a significant impact on the daily life of those affected, as well as their families, including high morbidity and mortality. There are currently no approved therapies available for the treatment of chILD.
“Some children with interstitial lung disease may develop serious fibrosis that progresses,” said the coordinating investigator Prof. Robin Deterding, M.D., Director of the Breathing Institute, Children's Hospital Colorado. “Though the underlying causes of pulmonary fibrosis may be different in children, we’re excited to determine if treating the mechanism of fibrosis improves children’s lung fibrosis as it does in adults.”
Nintedanib, which is marketed as Ofev® , is currently approved in more than 80 countries for the treatment of people living with idiopathic pulmonary fibrosis (IPF).4 It is also approved in more than 40 countries as the first and only therapy to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILD (SSc-ILD).5 Ofev® recently also obtained approval in the USA, Canada, Japan, Brazil, Argentina and the EU, for a third indication, as the first and only treatment for patients living with chronic fibrosing ILDs with a progressive phenotype.2,3
“Boehringer Ingelheim is proud to start this trial to provide valuable insights as we evaluate this potential treatment for children and adolescents with these rare and heterogenous conditions for which there are currently no treatments with proven efficacy and no randomized controlled trials,” said Dr Susanne Stowasser, Associate Head of Medicine Pulmonology at Boehringer Ingelheim. “This study represents our ongoing commitment to address unmet needs and advance research for adult and pediatric patients living with pulmonary fibrosis.”
~ENDS~
For references and notes to editors, please visit: http://www.boehringer-ingelheim.com/press-release/inpedildtrialenrollment
View source version on businesswire.com: https://www.businesswire.com/news/home/20200812005420/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Core42 “Maximus-384” Cluster Secures Top 20 Ranking on the Global TOP500 Supercomputers List18.11.2025 14:24:00 CET | Press release
Core42, A G42 Company, secures #20 position with its AMD Instinct MI300X GPU cluster in Buffalo, New York.Results announced ahead of Supercomputing 2025.Collaboration between Core42, Broadcom and Arista Networks delivers a top performing and reliable HPC network with fast data transfers and minimal latency. Core42, a G42 company specializing in sovereign cloud and AI infrastructure, announced that itsMaximus-384 supercomputer has been ranked No. 20 globally on the TOP500 List, the industry’s most recognized benchmark for publicly known supercomputing systems. The ranking highlights the performance of the AMD Instinct™ MI300X GPU-based “Maximus” cluster, operated at the company’s facility in Buffalo, New York and released ahead of Supercomputing 2025, the leading global conference for HPC. The TOP500 list tracks performance trends across the global supercomputing systems using the High Performance Linpack benchmark (HPL) benchmark. Securing a top-20 position reflects exceptional enginee
Armis Streamlines Network and Security Operations by Utilizing Keysight’s Application Fusion Platform18.11.2025 14:00:00 CET | Press release
Armis' technology can now run on the Keysight Vision E1S network packet brokers using the open interface known as Application Fusion, empowering security teams to enhance efficiency, reduce infrastructure costs and strengthen their security posture Armis, the cyber exposure management & security company, and Keysight Technologies, Inc. (NYSE: KEYS) today announced that Armis’ cyber exposure management technology will now run directly on the Keysight Vision E1S network packet brokers, with additional models expected to support Application Fusion in the future. Through the Application Fusion interface, Armis’ technology can now run directly on the Keysight network packet brokers, combining network visibility with continuous cyber exposure management and security capabilities. By providing immediate, actionable insights across the entire network, without the need for additional hardware, security teams can respond to threats faster, proactively reduce risk and increase operational efficie
Parse Biosciences Announces FFPE-compatible Barcoding Technology for Whole Transcriptome Single Cell Analysis18.11.2025 14:00:00 CET | Press release
New method enables single cell discovery from archived tissue samples, expanding access to translational and clinical research Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced a breakthrough technology that unlocks the full potential of formalin-fixed, paraffin-embedded (FFPE) samples. By enabling whole transcriptome capture from archived tissues at single cell resolution, this innovation opens new possibilities for discovery in oncology, translational research, and precision medicine. The use of FFPE samples for single cell RNA sequencing (scRNA-seq) has traditionally been limited to profiling a predefined list of genes due to RNA degradation and fragmentation, reducing transcriptome coverage and discovery potential. Parse’s breakthrough overcomes these challenges with a novel split-pool combinatorial barcoding method that enables true transcriptome-wide scRNA-seq of FFPE-preserved tissues through its unique RNA captu
KP Labs and Frontgrade Gaisler Join Forces to Advance Fault-Tolerant Computing for Next-Generation Space Missions18.11.2025 14:00:00 CET | Press release
KP Labs, a European Leader in delivering autonomous systems for space applications and Frontgrade™ Gaisler Technologies, a leading provider of high-reliability electronic solutions for space and national security missions have signed a Memorandum of Understanding during the Space Tech Expo Europe in Bremen, Germany. The agreement establishes a framework for collaboration in developing and validating advanced on-board computing architectures designed to increase the autonomy and resilience of future space missions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251118359687/en/ As satellite operators and mission designers increasingly rely on on-board data processing and autonomy, maintaining fault tolerance and reliability has become a critical priority. To meet these demands, modern spacecraft integrates radiation-hardened components and advanced FDIR (Fault Detection, Isolation and Recovery) systems that ensure stable oper
ACE Fiber uses Adtran’s Mosaic One Clarity AI solution for proactive assurance, faster resolution and fewer truck rolls18.11.2025 14:00:00 CET | Press release
News summary: Mississippi provider’s fiber expansion increased operational complexity, driving the need for quicker troubleshooting and fewer site visits With Adtran’s Mosaic One Clarity, built on its REAL AI platform, ACE Fiber is transforming operations to prevent issues and reduce costs Early results show up to 75% fewer tickets in the first month, cutting service calls and improving customer experiences Adtran today announced that ACE Fiber, the broadband subsidiary of Mississippi’s ACE Power, is using its Mosaic One Clarity solution, built on the REAL AI platform, to move from reactive troubleshooting to proactive assurance across ACE Fiber’s expanding network. Mosaic One Clarity consolidates network and in-home data, identifies likely root causes and provides guided actions that help teams resolve issues faster and avoid unnecessary site visits. By detecting early signs of fiber performance issues and showing which subscribers are affected, Mosaic One Clarity enables more right-f
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom